|
|
|
MIRA INFORM REPORT
|
Report No. : |
501857 |
|
Report Date : |
11.04.2018 |
IDENTIFICATION DETAILS
|
Name : |
LIQUEFY HEALTH P L |
|
|
|
|
Registered Office : |
Level 8, 32 Walker Street North
Sydney NSW, 2060 |
|
|
|
|
Country : |
Australia |
|
|
|
|
Date of Incorporation : |
22.08.2016 |
|
|
|
|
Legal Form : |
Australian Proprietary Company |
|
|
|
|
Line of Business : |
The subject operates in the manufacture and distribution of a
range of health drinks |
|
|
|
|
No. of Employees : |
15 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
B |
|
Credit Rating |
Explanation |
Rating Comments |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
Australia |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
AUSTRALIA - ECONOMIC OVERVIEW
Following two decades of continuous growth, low unemployment, contained inflation, very low public debt, and a strong and stable financial system, Australia enters 2018 facing a range of growth constraints, principally driven by the sharp fall in global prices of key export commodities. Demand for resources and energy from Asia and especially China has stalled and sharp drops in current prices have impacted growth.
The services sector is the largest part of the Australian economy, accounting for about 70% of GDP and 75% of jobs. Australia was comparatively unaffected by the global financial crisis as the banking system has remained strong and inflation is under control.
Australia benefited from a dramatic surge in its terms of trade in recent years, although this trend has reversed due to falling global commodity prices. Australia is a significant exporter of natural resources, energy, and food. Australia's abundant and diverse natural resources attract high levels of foreign investment and include extensive reserves of coal, iron, copper, gold, natural gas, uranium, and renewable energy sources. A series of major investments, such as the US$40 billion Gorgon Liquid Natural Gas Project, will significantly expand the resources sector.
Australia is an open market with minimal restrictions on imports of goods and services. The process of opening up has increased productivity, stimulated growth, and made the economy more flexible and dynamic. Australia plays an active role in the WTO, APEC, the G20, and other trade forums. Australia’s free trade agreement (FTA) with China entered into force in 2015, adding to existing FTAs with the Republic of Korea, Japan, Chile, Malaysia, New Zealand, Singapore, Thailand, and the US, and a regional FTA with ASEAN and New Zealand. Australia continues to negotiate bilateral agreements with India and Indonesia, as well as larger agreements with its Pacific neighbors and the Gulf Cooperation Council countries, and an Asia-wide Regional Comprehensive Economic Partnership that includes the 10 ASEAN countries and China, Japan, Korea, New Zealand and India.
|
Source
: CIA |
NOTE
In absence of financials, no credit limit could be recommended.
Company
NAME
LIQUEFY HEALTH P/L
ACN
614363174
ABN
62614363174
Summary
Panel
|
Established |
2017 |
|
|
Incorporated |
2016 |
|
|
Line of Business |
Manufacture and distribution of health drinks |
|
|
Status |
Trading |
|
|
Chief Executive Officer |
BROWNE, TOBY ROWLEY |
|
|
Adverse Listings |
|
|
EXECUTIVE
SUMMARY
After a period of research and development the subject commenced
trading activities in August 2017.
Details pertaining to the subject’s financial position and
projections were not released for the current enquiry.
The subject is majority owned by Pharm-A-Care Laboratories P/L.
For the year ended 30 June 2016 this entity recorded revenue of $298,563,340
which resulted in an operating profit after tax of $14,606,537.
The establishment of the subject has been funded through the
backing of the shareholders.
CORPORATE SEARCH
Company Type Australian Proprietary Company
Status Registered
Incorporation Date 22 Aug 2016
Incorporation State NSW
Registered Office LEVEL 8, 32 WALKER STREET
NORTH SYDNEY NSW, 2060
Current Directors Total: 1
Director Name BROWNE, TOBY ROWLEY
Appointment Date 22 Aug 2016
Date of Birth 22 Apr 1953
Place of Birth SYDNEY NSW
Gender MALE
Resident Overseas N
Address 140A CRESCENT RD, NEWPORT
NSW 2106
Current Other Officers Total: 1
Officer Role Alternate Director
Officer Name BROWNE, ALYSE
Appointment Date 17 Jan 2018
Date of Birth 18 Jun 1987
Place of Birth SYDNEY NSW
Address 140A THE CRESCENT NEWPORTNSW,
2106
Current Other Organisation Officers
Total: 1
Officer Role Ultimate Holding Company
Officer Name PHARM-A-CARE LABORATORIES
PTY. LIMITED
ACN 003468219
Appointment Date -
Address -
Company Shares Total: 100 Amount: $100
Class ORD SHARES [ORD]
Number of Shares Issued 100
Paid Capital $100.00
Total Amount Due and Payable $0.00
Current Shareholders
Shareholder Name NATURAL BIO PTY
LIMITED
ACN 101785737
ABN 29101785737
Address 18 JUBILEE AVENUE
WARRIEWOOD NSW, 2102
Class
ORD
Number Held 100
Beneficially Held Y
Fully Paid Y
Jointly Held N
SECURITY
INTERESTS
Effective 30 January 2012 the Personal Property Securities
Register (PPSR) was introduced to give
the different Commonwealth, State and Territory laws and registers regarding
security interests in personal property under one national system.
As a result of PPS Reform a number of existing Commonwealth, State
and Territory personal property security registers will close. Interests
registered on existing security interest registers will be migrated to the
national PPS Register. Subsequently Registered Charges are no longer lodged
with the Australian Securities and Investments Commission (ASIC).
Please contact us should you require a search of the PPSR.
BUSINESS STRUCTURE
TRADING ADDRESS 16
Jubilee Ave
WARRIEWOOD,
NSW
TELEPHONE (612)
9503 1098
WEBSITE https://www.liquefy.com.au
HOLDING ENTITY NATURAL
BIOP/L
ULTIMATE HOLDING
ENTITY PHARM-A-CARE
LABORATORIES P/L
BANK ST
GEORGE BANK
EMPLOYEES 15
BACKGROUND
The subject was incorporated in New South Wales on 22 August 2016
under the current style.
After a period of research and development the subject commenced
trading activities in August 2017.
OPERATIONS
The subject operates in the manufacture and distribution of a range
of health drinks
Activities are conducted from premises located at the above listed
trading address.
ADVERSE
A search of of on failed to trace any litigation listed against
the subject at that date.
FINANCES
The subject is not required to lodge financial statements with the
Australian Securities and Investments Commission.
During the current interview conducted with the subject’s
financial controller Julian, he advised that the subject commenced trading
activities in August 2017.
Details pertaining to the subject’s financial position and
projections were not released for the current enquiry.
The subject is majority owned by Pharm-A-Care Laboratories P/L.
For the year ended 30 June 2016 this entity recorded revenue of $298,563,340 which
resulted in an operating profit after tax of $14,606,537.
The establishment of the subject has been funded through the
backing of the shareholders.
TRADE SURVEY
A trade survey on the subject traced the following accounts:
1. (Sensient) Nominated
supplier failed to respond to correspondence despite chasing.
2. (Essence Group)
Nominated supplier failed to respond to correspondence despite chasing.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 64.94 |
|
|
1 |
INR 91.75 |
|
Euro |
1 |
INR 79.90 |
|
AUD |
1 |
INR 65.08 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
NIY |
|
|
|
|
Report Prepared
by : |
TRU |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.